WO2008152537A3 - Humanized monoclonal antibodies - Google Patents

Humanized monoclonal antibodies Download PDF

Info

Publication number
WO2008152537A3
WO2008152537A3 PCT/IB2008/052038 IB2008052038W WO2008152537A3 WO 2008152537 A3 WO2008152537 A3 WO 2008152537A3 IB 2008052038 W IB2008052038 W IB 2008052038W WO 2008152537 A3 WO2008152537 A3 WO 2008152537A3
Authority
WO
WIPO (PCT)
Prior art keywords
monoclonal antibodies
mabs
humanized
humanized monoclonal
studies
Prior art date
Application number
PCT/IB2008/052038
Other languages
French (fr)
Other versions
WO2008152537A2 (en
Inventor
Mitali Samaddar
Kemburu Prasanna Kumar
Gosala Jaya Lakshmi
Chigurupati Jayaram
Original Assignee
Zenotech Laboratories Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zenotech Laboratories Limited filed Critical Zenotech Laboratories Limited
Publication of WO2008152537A2 publication Critical patent/WO2008152537A2/en
Publication of WO2008152537A3 publication Critical patent/WO2008152537A3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46Hybrid immunoglobulins
    • C07K16/461Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464Igs containing CDR-residues from one specie grafted between FR-residues from another
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567Framework region [FR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

Humanized MAbs are designed, created and produced using a series of innovative processes comprising of computational analysis, modeling studies, rationale assessment and selection of humanized sequences, an efficient recombinant DNA expression system and functional studies to interrogate the therapeutic properties of the MAbs. The invention also provides an economic and scalable process of producing the monoclonal antibodies in large quantities and find use in the treatment of human diseases like cancer. Also described is a panel of novel humanized MAbs directed against the human EGFR that acts as receptor antagonists and are substantially non-immunogenic.
PCT/IB2008/052038 2007-06-14 2008-05-23 Humanized monoclonal antibodies against human epidermal growth factor receptor, use and method thereof WO2008152537A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1236CH2007 2007-06-14
IN1236/CHE/2007 2007-06-14

Publications (2)

Publication Number Publication Date
WO2008152537A2 WO2008152537A2 (en) 2008-12-18
WO2008152537A3 true WO2008152537A3 (en) 2010-04-08

Family

ID=40130263

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2008/052038 WO2008152537A2 (en) 2007-06-14 2008-05-23 Humanized monoclonal antibodies against human epidermal growth factor receptor, use and method thereof

Country Status (1)

Country Link
WO (1) WO2008152537A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
NZ630020A (en) 2012-03-08 2016-08-26 Halozyme Inc Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof
KR20160055253A (en) 2013-09-12 2016-05-17 할로자임, 아이엔씨 Modified anti-epidermal growth factor receptor antibodies and methods of use thereof
WO2017161206A1 (en) 2016-03-16 2017-09-21 Halozyme, Inc. Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6114146A (en) * 1994-11-14 2000-09-05 Baxter Aktiengesellschaft Expression plasmid, a fusion protein, a transfected eukaryotic cell line, a method of producing foreign proteins, a foreign protein preparation as well as a pharmaceutical composition
US6602684B1 (en) * 1998-04-20 2003-08-05 Glycart Biotechnology Ag Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6114146A (en) * 1994-11-14 2000-09-05 Baxter Aktiengesellschaft Expression plasmid, a fusion protein, a transfected eukaryotic cell line, a method of producing foreign proteins, a foreign protein preparation as well as a pharmaceutical composition
US6602684B1 (en) * 1998-04-20 2003-08-05 Glycart Biotechnology Ag Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ROGUSKA ET AL.: "Humanization of murine monoclonal antibodies through variable domain resurfacing", PNAS, vol. 91, 1994, pages 969 - 973, XP002271704, DOI: doi:10.1073/pnas.91.3.969 *

Also Published As

Publication number Publication date
WO2008152537A2 (en) 2008-12-18

Similar Documents

Publication Publication Date Title
NL301196I2 (en) inebilizumab
WO2007044756A3 (en) Monoclonal antibodies recognizing human ccr8
PH12015500782A1 (en) Human cytomegalovirus neutralizing antibodies and use thereof
TW200738748A (en) Human monoclonal antibody human CD134 (OX40) and methods of making and using same
WO2006099875A8 (en) Antibodies against cd38 for treatment of multiple myeloma
WO2009083009A3 (en) Monoclonal antibodies against cd32b
WO2011147982A3 (en) Monoclonal antibodies against her2 epitope
WO2010129033A3 (en) Modified antibodies for passive immunotherapy
NZ610734A (en) Human antibodies to the glucagon receptor
EP3539988A3 (en) Monoclonal antibodies against her2
WO2010017103A3 (en) Fully human anti-human nkg2d monoclonal antibodies
NZ591471A (en) Antibodies to ccr2
MX2010009190A (en) HUMANIZED ANTI-C5aR ANTIBODIES.
TN2010000210A1 (en) Monoclonal antibodies that bind to hgm-csf and medical compositions comprising same
WO2005103081A3 (en) Human monoclonal antibodies against cd20
MX355181B (en) Human antibodies against human tissue factor.
WO2006089133A8 (en) Anti-cd19 antibodies and uses in oncology
MY157173A (en) Modified humanised anti-interleukin-18
WO2011143624A3 (en) Humanized and chimeric monoclonal antibodies to cd47
DOP2009000221A (en) UNION PROTEINS, INCLUDING ANTIBODIES, ANTIBODY DERIVATIVES AND ANTIBODY FRAGMENTS, WHICH SPECIFICALLY JOIN CD154 AND ITS USES
WO2011044311A3 (en) Generation, characterization and uses thereof of anti-her 3 antibodies
WO2010072740A3 (en) TARGETED BINDING AGENTS DIRECTED TO α5β1 AND USES THEREOF
WO2008152537A3 (en) Humanized monoclonal antibodies
PH12020551012A1 (en) Monoclonal antibodies and methods for using same
WO2008042941A3 (en) Humanized anti-ephb4 antibodies and their use in treatment of oncology and vasculogenesis-related disease

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08751313

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08751313

Country of ref document: EP

Kind code of ref document: A2